Literature DB >> 25280573

Adenomyosis and accompanying gynecological pathologies.

Mine Genc1, Berhan Genc, Hakan Cengiz.   

Abstract

OBJECTIVE: The aim of the present study is to determine the potential risk factors for adenomyosis and to investigate its relationship with accompanying gynecological pathologies and clinical characteristics. MATERIALS AND
METHOD: This study is a retrospective analysis of 945 patients who underwent hysterectomy between May 2005 and January 2013 at the Sifa University Medical Faculty Hospital, Clinic of Obstetrics and Gynecology. The study included 327 patients with adenomyosis and 618 patients without adenomyosis by histopathological examination of the uterus.
RESULTS: There was a significant positive correlation between development of adenomyosis and presence of leiomyoma (p < 0.0001), history of previous abortion (p < 0.0001), history of previous pregnancy (p = 0.0002), and normal body mass index (p < 0.0001). However, no significant relationship existed between development of adenomyosis and smoking (p > 0.4300), normal delivery (p = 0.9600), cesarean delivery (p = 0.5705), endometrial hyperplasia (p = 0.1721), or ovarian endometriosis (p = 0.8595).
CONCLUSION: Women who are multiparous have leiomyoma, a previous history of abortion, and a normal body mass index are at increased risk for development of adenomyosis. Adenomyosis might be one cause of unexplained recurrent spontaneous abortion during pregnancy.

Entities:  

Mesh:

Year:  2014        PMID: 25280573     DOI: 10.1007/s00404-014-3498-8

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  8 in total

1.  Mice Uterine Stem Cells are Affected by Neonatal Endocrine Disruption & Initiate Uteropathies in Adult Life Independent of Circulatory Ovarian Hormones.

Authors:  Pushpa Singh; Siddhanath M Metkari; Deepa Bhartiya
Journal:  Stem Cell Rev Rep       Date:  2021-11-09       Impact factor: 6.692

2.  Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease.

Authors:  J M Puente; A Fabris; J Patel; A Patel; M Cerrillo; A Requena; J A Garcia-Velasco
Journal:  Reprod Biol Endocrinol       Date:  2016-09-20       Impact factor: 5.211

3.  Uterine Artery Embolization Versus Hysterectomy in the Treatment of Symptomatic Adenomyosis: Protocol for the Randomized QUESTA Trial.

Authors:  Annefleur Machteld de Bruijn; Wouter Jk Hehenkamp; Paul Nm Lohle; Judith Af Huirne; Jolanda de Vries; Moniek Twisk
Journal:  JMIR Res Protoc       Date:  2018-03-01

Review 4.  Adenomyosis and Infertility-Review of Medical and Surgical Approaches.

Authors:  Maria Szubert; Edward Koziróg; Olga Olszak; Klaudia Krygier-Kurz; Jakub Kazmierczak; Jacek Wilczynski
Journal:  Int J Environ Res Public Health       Date:  2021-01-30       Impact factor: 3.390

5.  Application of modified subtotal resection of adenomyosis combined with LNG-IUS and GnRH-a sequential therapy in severe adenomyosis: A case series.

Authors:  Zhenyue Qin; Zhiyong Dong; Huimin Tang; Shoufeng Zhang; Huihui Wang; Mingyue Bao; Weiwei Wei; Ruxia Shi; Jiming Chen; Bairong Xia
Journal:  Front Surg       Date:  2022-08-18

6.  Prototype and Chimera-Type Galectins in Placentas with Spontaneous and Recurrent Miscarriages.

Authors:  Laura Unverdorben; Thomas Haufe; Laura Santoso; Simone Hofmann; Udo Jeschke; Stefan Hutter
Journal:  Int J Mol Sci       Date:  2016-04-28       Impact factor: 5.923

7.  Uterine Artery Embolization for Symptomatic Adenomyosis: 7-Year Clinical Follow-up Using UFS-Qol Questionnaire.

Authors:  Annefleur M de Bruijn; Marieke Smink; Wouter J K Hehenkamp; Robbert J Nijenhuis; Albert J Smeets; Focco Boekkooi; Paul J H M Reuwer; Willem J Van Rooij; Paul N M Lohle
Journal:  Cardiovasc Intervent Radiol       Date:  2017-05-17       Impact factor: 2.740

8.  RhoA/ROCK/ARHGAP26 signaling in the eutopic and ectopic endometrium is involved in clinical characteristics of adenomyosis.

Authors:  Caixia Jiang; Wei Gong; Rong Chen; Huihui Ke; Xiaoyan Qu; Weihong Yang; Zhongping Cheng
Journal:  J Int Med Res       Date:  2018-11-02       Impact factor: 1.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.